<DOC>
	<DOC>NCT01402479</DOC>
	<brief_summary>Physiology of migraine involving renin-angiotensin systems (RAS) has been implicated. Ramipril is a broadly-used angiotensin-converting enzyme inhibitor. The investigators attempt to test the efficacy of ramipril on the prophylaxis of migraine attacks.</brief_summary>
	<brief_title>An Open-labeled Trial of Ramipril in Patients With Migraine</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Migraine Disorders</mesh_term>
	<mesh_term>Ramipril</mesh_term>
	<criteria>Patients with chronic migraine are included in this study. Migraineurs should be aged 20 to 70 years old with the ability to read and understand the selfreport scales, including the headache diary, used in this study. 1. Medication overuse headache are excluded in this study. 2. Treatment with other ACEI or medication that may affect ARS 3. Treatment with migraine prophylactic medications or antihypertensive agents including Î² adrenergic receptor or calcium channel blockers 4. Past history of hepatic or renal dysfunction; an abnormal electrocardiography; a psychiatric disorder; a history of substance abuse; pregnancy or lactation; use of antipsychotics, antidepressants, or antianxiety drugs.</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>migraine,</keyword>
	<keyword>ramipril,</keyword>
	<keyword>hypertension</keyword>
</DOC>